SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

Nasus Pharma has filed to raise $11M in an IPO of its ordinary shares, according to SEC F-1 registration. Read why my outlook ...

ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the ...

The rapid lateral flow assay from Lumos Diagnostics distinguishes bacterial and nonbacterial respiratory infections using a drop of blood.

The benchmarking report used a rigorous methodology to ensure results reflected ICON’s true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...

Ultragenyx's high burn rate, costly R&D, and recent setbacks increase dilution risk, impacting future profitability. Learn ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Fact checked by Nick Blackmer Karen Peterson was diagnosed with stage 1 triple-negative breast cancer in 2015. After undergoing three months of chemotherapy with difficult side effects, she made the ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.